Arcutis Biotherapeutics starts eczema drug study

You are here: Home > Biotech > Current Article

Arcutis Biotherapeutics starts eczema drug study

By Staff Report / Wednesday, April 22nd, 2020 / Comments Off on Arcutis Biotherapeutics starts eczema drug study

Westlake Village biotech startup Arcutis Biotherapeutics, targeting dermatological diseases, launched a new clinical study of its topical drug to treat chronic hand eczema April 21 with the enrollment of its first patient.  The 12-week Phase 1 study will test safety and tolerability of the product, called ARQ-252, in adult patients with hand eczema. ARQ-252 uses…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.